|
||||
 |
||||
Dockets
Management
|
||||
|
Up | AC What's New | AC Home Food and Drug Administration Oncologic Drugs
Advisory Committee MORNING SESSIONBriefing Information Food and Drug Administration Disclaimer Portions of these documents may have been determined to be exempt from disclosure under the Freedom of Inoformation Act (the FOIA) (5 U.S.C. §552). These redacted portions will appear as white space on the screen or on the printed page. FDA Backgrounder – March 13. (a.m. Session) AFTERNOON SESSIONEli Lilly & Company - Briefing Material The statements contained in this document(s) are not those of the FDA, and the FDA does not necessarily agree with these statements. FDA has not made a final determination about the issues to be discussed at the Advisory Committee Meeting. Food and Drug Administration Disclaimer Portions of these documents may have been determined to be exempt from disclosure under the Freedom of Inoformation Act (the FOIA) (5 U.S.C. §552). These redacted portions will appear as white space on the screen or on the printed page.
|
